Novel Methods for Reducing Inflammation and Treating Diseases such as Parkinson's and Alzheimer's Disease

Microglia activation leads to inflammation mediated dopaminergic degeneration in the brain of patients with Parkinson and Alzheimer's Disease. Thus Identification of drugs that reduce microglia activation could prevent or reverse neuronal degeneration in these diseases and other degenerative CNS disorders.

This invention describes small-peptide and non-peptide molecules that inhibit microglia activation and prevent neuronal degeneration with a bi-modal dose response curve. The non-peptide compounds have also been shown to prevent dopamine neuronal degeneration in animal models. This invention provides compositions and methods for inhibiting inflammatory mechanisms and treating inflammation-related condition by administering ultra-low (femto-molar) doses of at least one compound of the invention. These compounds include morphinans, opioid peptides, and the tripeptide GGF.

Potential Commercial Applications: Competitive Advantages:
  • Therapeutic treatment of Parkinson, Alzheimers and other degenerative CNS disorders.
  • These compounds are active at ultra-low concentrations.

Development Stage:
  • Early-stage
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)


Jau-Shyong Hong (NIEHS)  ➽ more inventions...

Liya Qin (NIEHS)  ➽ more inventions...

Guorong Li (NIEHS)  ➽ more inventions...

MIchelle Block (NIEHS)  ➽ more inventions...

Wei Zhang (NIEHS)  ➽ more inventions...

Po-See Chen (NIEHS)  ➽ more inventions...

Giia-Shuen Peng (NIEHS)  ➽ more inventions...

Intellectual Property:
U.S. Pat: 9,498,511 issued 2016-11-22
U.S. Pat: 8,796,302 issued 2014-08-05
U.S. Pat: 8,088,787 issued 2012-01-03
US Application No. 60/570,566
US Application No. 11/596,296

Liu B, et al. PMID 10991969

Collaboration Opportunity:

The NIEHS is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Sally E. Tilotta, Ph.D. at

Licensing Contact:
Uri Reichman, Ph.D., M.B.A.
Phone: 301-435-4616

OTT Reference No: E-130-2004-0
Updated: May 4, 2018